Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02447302 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
A Phase 2 study, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT02447302: Completed Phase 2 study, sponsored by Arena Pharmaceuticals.
NCT02447302 is a Phase 2 study that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 156 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02447302, a Phase 2 study, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
Primary Outcome
The adapted MCS was used to measure disease activity of ulcerative colitis. It consisted of 3 subscores (stool frequency, rectal bleeding, and findings of endoscopy), each of which was rated on a scale from 0 to 3, indicating normal to severe. The adapted MCS was calculated as the sum of the 3 subscores, and the overall score values ranged from 0 to 9, with a higher score indicating more severe disease. Multiple imputation method was used to handle missing data.
Interventions
- DRUG Placebo
- DRUG Etrasimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2015-10-15 |
| Est. Completion | 2018-02-14 |
| Phase | Phase 2 |
What the finished NCT02447302 record still lists
NCT02447302 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02447302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02447302 about?
NCT02447302 is a clinical study titled "Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis". The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
What is the current status of trial NCT02447302?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2015-10-15. Estimated completion is 2018-02-14.
What interventions are being tested in trial NCT02447302?
The interventions under investigation include: Placebo (DRUG), Etrasimod (DRUG).
Who is sponsoring clinical trial NCT02447302?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02447302's enrollment target sits among peer trials
156 445th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI